XSHE
002014
Market cap1.02bUSD
Oct 09, Last price
11.31CNY
1D
1.07%
1Q
6.30%
Jan 2017
27.24%
IPO
435.49%
Name
Huangshan Novel Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1992 and headquartered in Huangshan, China, Huangshan Novel Co., Ltd. specializes in the manufacturing and supply of packaging materials, primarily serving the Chinese market. The company's diverse product portfolio encompasses various films, such as color-printed plastic, flexible laminates, vacuum-metallized, and multi-functional types. It also provides medical packaging, breathable and protective membranes, and injection molding compounds. These materials are widely applied across numerous industries, including food and beverage, daily consumer products, pharmaceuticals, agricultural chemicals, electronics, and building materials. Beyond its domestic operations, the firm actively exports its goods to international destinations, such as Europe, the United States, Mexico, Japan, the Middle East, and other regions in Asia.
Key people
Lei Jiang
Chairman of the Board · since 2025
Xu Wu
Finance Director · since 2022
Jian Pan
General Manager, Director · since 2025
Changchun Wang
Deputy General Manager · since 2022
Yongliang Tang
Secretary of the Board · since 2019
Ran Bao
Director · since 2025
Minjian Gao
Director · since 2001
Director · since 2016
Jun Sun
Deputy General Manager, Director · since 2025
Haifeng Wan
Chief Human Resources Officer, Staff Elected Director · since 2025
Director · since 2016
Bo Yu
Director · since 2022
Vice Chairman of the Board · since 2016
Meixia An
Independent Director · since 2025
Independent Director · since 2022
Independent Director · since 2023
Independent Director · since 2022
Yuehong Zhang
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||